RxDoctor Payments Data

Kirstin Donnelly, APRN

Family · Bardstown, KYNPI 1831587831

Payments from drug & device makers

$4,031in general payments, 2019–2025

Across 292 payments — averaging $13.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$781
  • Novo Nordisk$736
  • Pfizer$487
  • AstraZeneca$311
  • Amgen$282
  • Johnson & Johnson$137
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,031100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,031 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$63,238
Medicare patients
151
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide41$43,844
OzempicSemaglutide34$36,643
EliquisApixaban21$26,430
JanuviaSitagliptin Phosphate20$19,437
FarxigaDapagliflozin Propanediol13$12,028
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,005
Tresiba Flextouch U-100Insulin Degludec11$6,716
SymbicortBudesonide/Formoterol Fumarate12$3,438
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,942
Levothyroxine Sodium235$1,919
Celecoxib16$1,724
Lidocaine14$1,613
Ondansetron OdtOndansetron17$1,607
Albuterol Sulfate HfaAlbuterol Sulfate75$1,203
Metoprolol Succinate75$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$119$43,84441 claims
Novo NordiskOzempic$736$36,64334 claims
PfizerEliquis$487$26,43021 claims
MerckJanuvia$73$19,43720 claims
AstraZenecaFarxiga, Symbicort$311$15,46525 claims
GSKAnoro Ellipta$68$7,00511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Bardstown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →